Foretinib

Generic Name: Foretinib

Brand Names: -

Drug Type: Small Molecule

Chemical Formula: C_₃₄H_₃₄F_₂N_₄O_₆

CAS Number: 849217-64-7

Unique Ingredient Identifier: 81FH7VK1C4

Background: Foretinib has been used in trials studying the treatment of Cancer, Breast Cancer, Carcinoma, Renal Cell, Recurrent Breast Cancer, and Neoplasms, Head and Neck, among others. Foretinib is an orally available small molecule compound designed to target multiple RTKs implicated in the development, progression and spread of cancer. It inhibits the activation of ...

Associated Conditions: -

Associated Therapies: -

Clinical Trials

A Study to Evaluate Foretinib in Subjects With Non-Small-Cell Lung Cancer

Phase 2

Withdrawn

Conditions: Cancer

Interventions: Drug: Foretinib
Drug: Erlotinib

First Posted Date: 2014-01-13

Last Posted Date: 2014-05-19

Lead Sponsor: GlaxoSmithKline

Registration Number: NCT02034097

A Study of Foretinib in Patients With Recurrent/Metastatic Breast Cancer

Phase 2

Completed

Conditions: Recurrent Breast Cancer

Interventions: Drug: Foretinib

First Posted Date: 2010-06-22

Last Posted Date: 2023-08-04

Lead Sponsor: NCIC Clinical Trials Group

Target Recruit Count: 47

Registration Number: NCT01147484

Locations: 🇨🇦
QEII Health Sciences Centre, Halifax, Nova Scotia, Canada
🇨🇦
London Regional Cancer Program, London, Ontario, Canada
🇨🇦
Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton, Ontario, Canada

and more 6 locations

Study of Foretinib in Combination With Lapatinib in Patients With Metastatic Breast Cancer

Phase 1

Completed

Conditions: Breast Cancer

Interventions: Drug: Foretinib
Drug: Lapatinib

First Posted Date: 2010-06-07

Last Posted Date: 2023-08-04

Lead Sponsor: NCIC Clinical Trials Group

Target Recruit Count: 19

Registration Number: NCT01138384

Locations: 🇨🇦
BCCA - Cancer Centre for the Southern Interior, Kelowna, British Columbia, Canada
🇨🇦
Cancer Centre of Southeastern Ontario at Kingston, Kingston, Ontario, Canada
🇨🇦
London Regional Cancer Program, London, Ontario, Canada

and more 2 locations

Safety Study of Foretinib (GSK1363089) in Adults With Liver Cancer

Phase 1

Completed

Conditions: Carcinoma, Hepatocellular

Interventions: Drug: Foretinib

First Posted Date: 2009-06-15

Last Posted Date: 2017-07-18

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 45

Registration Number: NCT00920192

Locations: 🇹🇭
GSK Investigational Site, Khon Kaen, Thailand

Prev
1
Next

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy